Strategies such as arginine deiminase and human arginase (hArg) exploit arginine auxotrophy in tumors, particularly those with deficiencies in arginosuccinate synthesis 1 (ASS1) or ornithine transcarbamylase (OCT), including hepatocellular carcinoma and melanoma. This evidence concerns the gene ASS1 and hepatocellular carcinoma.